We could not find any results for:
Make sure your spelling is correct or try broadening your search.
BioLineRx Appoints Dr. Sandra Panem to Board of Directors PR Newswire JERUSALEM, Feb. 24, 2014 JERUSALEM, Feb. 24, 2014 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage...
Paine & Partners Forms New Advisory Relationship With SDA Ventures LLC Will Work with SDA Principals Steve Dubin and David Abramson to Identify and Execute Investment Opportunities in the Human...
Martek Biosciences Inducted into Small Business Innovation Research (SBIR) Hall of Fame Martek One of Only Eight Companies Inducted into the Inaugural SBIR Hall of Fame PR Newswire COLUMBIA, Md...
Standard & Poor's Announces Changes to U.S. Index PR Newswire NEW YORK, Feb. 14, 2011 NEW YORK, Feb. 14, 2011 /PRNewswire/ -- S&P will make the following changes to SmallCap 600...
STEVENSON, MD -- (Marketwire) -- 01/21/11 -- Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the Maryland Circuit Court, Howard County, on...
Egleston Law Firm announces an investigation into possible breaches of fiduciary duty in connection with the proposed acquisition of Martek Biosciences Corporation (NASDAQ:...
Bull & Lifshitz, LLP announces an investigation into possible breaches of fiduciary duty in connection with the proposed acquisition of Martek Biosciences Corporation (NASDAQ:...
Law Offices of Howard G. Smith announces that it is investigating potential claims against the board of directors of Martek Biosciences Corporation (“Martek” or the “Company”...
Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/matk) is investigating potential claims against the board of directors of Martek Biosciences Corp. ("Martek" or the "Company...
The Law Office of Joseph Klein is investigating the Board of Directors of Martek Biosciences Corporation (“Martek”) (NasdaqGS: MATK) for possible breaches of fiduciary duty and...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions